Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) EPS (Basic) (2016 - 2025)

Dexcom (DXCM) has disclosed EPS (Basic) for 16 consecutive years, with $0.68 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 78.95% to $0.68 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.14, a 46.58% increase, with the full-year FY2025 number at $2.14, up 46.58% from a year prior.
  • EPS (Basic) was $0.68 for Q4 2025 at Dexcom, down from $0.73 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.73 in Q3 2021 to a low of -$0.01 in Q4 2021.
  • A 5-year average of $0.37 and a median of $0.32 in 2023 define the central range for EPS (Basic).
  • Biggest YoY gain for EPS (Basic) was 2500.0% in 2022; the steepest drop was 64.38% in 2022.
  • Dexcom's EPS (Basic) stood at -$0.01 in 2021, then surged by 2500.0% to $0.24 in 2022, then soared by 175.0% to $0.66 in 2023, then plummeted by 42.42% to $0.38 in 2024, then skyrocketed by 78.95% to $0.68 in 2025.
  • Per Business Quant, the three most recent readings for DXCM's EPS (Basic) are $0.68 (Q4 2025), $0.73 (Q3 2025), and $0.46 (Q2 2025).